Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes

Cancer Cell

Volumn 29, Issue 3, 2016, Pages 379-393

  Johann, Pascal D ^a,b   Erkek, Serap ^a,c   Zapatka, Marc ^a   Kerl, Kornelius ^d   Buchhalter, Ivo ^a   Hovestadt, Volker ^a   Jones, David T W ^a   Sturm, Dominik ^a,b   Hermann, Carl ^a   Segura Wang, Maia ^c   Korshunov, Andrey ^a,b   Rhyzova, Marina ^e   Gröbner, Susanne ^a   Brabetz, Sebastian ^a   Chavez, Lukas ^a   Bens, Susanne ^f   Gröschel, Stefan ^g   Kratochwil, Fabian ^a   Wittmann, Andrea ^a   Sieber, Laura ^a   Geörg, Christina ^g   Wolf, Stefan ^a   Beck, Katja ^a   Oyen, Florian ^h   Capper, David ^a,b   van Sluis, Peter ⁱ   Volckmann, Richard ⁱ   Koster, Jan ⁱ   Versteeg, Rogier ⁱ   von Deimling, Andreas ^a,b   Milde, Till ^a,b   Witt, Olaf ^a,b   Kulozik, Andreas E ^b   Ebinger, Martin ^j   Shalaby, Tarek ^k   Grotzer, Michael ^k   Sumerauer, David ^l   Zamecnik, Josef ^l   Mora, Jaume ^m   Jabado, Nada ⁿ   Taylor, Michael D ^o   Huang, Annie ^o   Aronica, Eleonora ⁱ   Bertoni, Anna ^a   Radlwimmer, Bernhard ^a   Pietsch, Torsten ^p   Schüller, Ulrich ^q   Schneppenheim, Reinhard ^h   Northcott, Paul A ^a   Korbel, Jan O ^c   Siebert, Reiner ^f   Frühwald, Michael C ^r,s   Lichter, Peter ^a   Eils, Roland ^a   Gajjar, Amar ^t   Hasselblatt, Martin ^u   Pfister, Stefan M ^a,b   Kool, Marcel ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g C o Institut für Medizinische Biometrie und Informatik   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^l UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^m Section of Gastroenterology   (Spain)

ⁿ RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^o HOSPITAL FOR SICK CHILDREN   (Canada)

^p UNIVERSITY OF BONN   (Germany)

^q UNIVERSITY OF MUNICH   (Germany)

^r Children's Hospital Augsburg   (Germany)

^s Childrens Hospital Augsburg and EU RHAB Registry   (Germany)

^t ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^u UNIVERSITY HOSPITAL MÜNSTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PROTEIN; SMARCB1 PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; CANCER PROGNOSIS; CELL HETEROGENEITY; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 22; CHROMOSOME 22Q; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; ENHANCER REGION; EPIGENETICS; GENE EXPRESSION; HUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA SEQUENCE; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; UPREGULATION; BRAIN TUMOR; GENETIC EPIGENESIS; GENETICS; MUTATION; RHABDOID TUMOR; TERATOMA;

BRAIN NEOPLASMS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HUMANS; MUTATION; RHABDOID TUMOR; TERATOMA; TRANSCRIPTION FACTORS;

EID: 84959151000     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.02.001     Document Type: Article

References (36)

1. Bender S., Tang Y., Lindroth A.M., Hovestadt V., Jones D.T., Kool M., Zapatka M., Northcott P.A., Sturm D., Wang W., et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 2013, 24:660-672.
2. Berman B.P., Weisenberger D.J., Aman J.F., Hinoue T., Ramjan Z., Liu Y., Noushmehr H., Lange C.P., van Dijk C.M., Tollenaar R.A., et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 2012, 44:40-46.
3. Biegel J.A., Zhou J.Y., Rorke L.B., Stenstrom C., Wainwright L.M., Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999, 59:74-79.
4. Biggs P.J., Garen P.D., Powers J.M., Garvin A.J. Malignant rhabdoid tumor of the central nervous system. Hum. Pathol. 1987, 18:332-337.
5. Birks D.K., Donson A.M., Patel P.R., Dunham C., Muscat A., Algar E.M., Ashley D.M., Kleinschmidt-Demasters B.K., Vibhakar R., Handler M.H., Foreman N.K. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol. 2011, 13:1296-1307.
6. Chi S.N., Zimmerman M.A., Yao X., Cohen K.J., Burger P., Biegel J.A., Rorke-Adams L.B., Fisher M.J., Janss A., Mazewski C., et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J. Clin. Oncol. 2009, 27:385-389.
7. Faloon P.W., Bennion M., Weiner W.S., Smith R.A., Wurst J., Weiwer M., Hartland C., Mosher C.M., Johnston S., Porubsky P., et al. A Small Molecule Inhibitor of the MITF Molecular Pathway. Probe Reports from the NIH Molecular Libraries Program 2010, National Center for Biotechnology Information.
8. Ginn K.F., Gajjar A. Atypical teratoid rhabdoid tumor: current therapy and future directions. Front. Oncol. 2012, 2:114.
9. Hasselblatt M., Isken S., Linge A., Eikmeier K., Jeibmann A., Oyen F., Nagel I., Richter J., Bartelheim K., Kordes U., et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 2013, 52:185-190.
10. Hasselblatt M., Nagel I., Oyen F., Bartelheim K., Russell R.B., Schuller U., Junckerstorff R., Rosenblum M., Alassiri A.H., Rossi S., et al. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. Acta Neuropathol. 2014, 128:453-456.
11. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-Andre V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
12. Hnisz D., Schuijers J., Lin C.Y., Weintraub A.S., Abraham B.J., Lee T.I., Bradner J.E., Young R.A. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell 2015, 58:362-370.
13. Hovestadt V., Jones D.T., Picelli S., Wang W., Kool M., Northcott P.A., Sultan M., Stachurski K., Ryzhova M., Warnatz H.J., et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 2014, 510:537-541.
14. Jackson E.M., Sievert A.J., Gai X., Hakonarson H., Judkins A.R., Tooke L., Perin J.C., Xie H., Shaikh T.H., Biegel J.A. Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin. Cancer Res. 2009, 15:1923-1930.
15. Jin F., Li Y., Dixon J.R., Selvaraj S., Ye Z., Lee A.Y., Yen C.A., Schmitt A.D., Espinoza C.A., Ren B. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 2013, 503:290-294.
16. Johannessen C.M., Johnson L.A., Piccioni F., Townes A., Frederick D.T., Donahue M.K., Narayan R., Flaherty K.T., Wargo J.A., Root D.E., Garraway L.A. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013, 504:138-142.
17. Kieran M.W., Roberts C.W., Chi S.N., Ligon K.L., Rich B.E., Macconaill L.E., Garraway L.A., Biegel J.A. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr. Blood Cancer 2012, 59:1155-1157.
18. Kleihues P., Burger P.C., Scheithauer B.W. The new WHO classification of brain tumours. Brain Pathol. 1993, 3:255-268.
19. Lafay-Cousin L., Fay-McClymont T., Johnston D., Fryer C., Scheinemann K., Fleming A., Hukin J., Janzen L., Guger S., Strother D., et al. Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): the Canadian registry experience. Pediatr. Blood Cancer 2015, 62:1265-1269.
20. Lee R.S., Stewart C., Carter S.L., Ambrogio L., Cibulskis K., Sougnez C., Lawrence M.S., Auclair D., Mora J., Golub T.R., et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest 2012, 122:2983-2988.
21. Lister R., Ecker J.R. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res. 2009, 19:959-966.
22. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
23. Mack S.C., Witt H., Piro R.M., Gu L., Zuyderduyn S., Stutz A.M., Wang X., Gallo M., Garzia L., Zayne K., et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014, 506:445-450.
24. Maher B. ENCODE: the human encyclopaedia. Nature 2012, 489:46-48.
25. Pope B.D., Ryba T., Dileep V., Yue F., Wu W., Denas O., Vera D.L., Wang Y., Hansen R.S., Canfield T.K., et al. Topologically associating domains are stable units of replication-timing regulation. Nature 2014, 515:402-405.
26. Kundaje A., Meuleman W., Ernst J., Bilenky M., Yen A., Heravi-Moussavi A., Kheradpour P., Zhang Z., Wang J., et al. Integrative analysis of 111 reference human epigenomes. Nature 2015, 518:317-330. Roadmap Epigenomics Consortium.
27. Rorke L.B., Packer R.J., Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J. Neurosurg. 1996, 85:56-65.
28. Slavc I., Chocholous M., Leiss U., Haberler C., Peyrl A., Azizi A.A., Dieckmann K., Woehrer A., Peters C., Widhalm G., et al. Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. Cancer Med. 2014, 3:91-100.
29. Squire S.E., Chan M.D., Marcus K.J. Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy. J. Neurooncol. 2007, 81:97-111.
30. Sredni S.T., Tomita T. Rhabdoid tumor predisposition syndrome. Pediatr. Dev. Pathol. 2015, 18:49-58.
31. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., Pfaff E., Tonjes M., Sill M., Bender S., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22:425-437.
32. Tekautz T.M., Fuller C.E., Blaney S., Fouladi M., Broniscer A., Merchant T.E., Krasin M., Dalton J., Hale G., Kun L.E., et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J. Clin. Oncol. 2005, 23:1491-1499.
33. Torchia J., Picard D., Lafay-Cousin L., Hawkins C.E., Kim S.K., Letourneau L., Ra Y.S., Ho K.C., Chan T.S., Sin-Chan P., et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol. 2015, 16:569-582.
34. Uen Y.H., Fang C.L., Hseu Y.C., Shen P.C., Yang H.L., Wen K.S., Hung S.T., Wang L.H., Lin K.Y. VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characterization. Scientific Rep. 2015, 5:9360.
35. Versteege I., Sevenet N., Lange J., Rousseau-Merck M.F., Ambros P., Handgretinger R., Aurias A., Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998, 394:203-206.
36. Wilson B.G., Roberts C.W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011, 11:481-492.